2026

The General Meeting of Shareholders approved the distribution of the 2025 profit and the capital increase of Tchaikapharma High Quality Medicines AD
At the General Meeting of Shareholders held on 24 June 2026, the shareholders of Tchaikapharma High Quality Medicines AD approved the proposal of the Board of Directors regarding the distribution of the Company’s 2025 profit and the increase of its share capital.
The resolution was adopted unanimously with 100% of the capital represented at the General Meeting, corresponding to 91% of the Company’s registered share capital.

The General Meeting resolved that the net profit for 2025, amounting to EUR 3,075,294.29, be allocated as follows:
• EUR 307,529.43 (10% of the profit) shall be allocated to the statutory reserve;
• EUR 13,764.86 shall be allocated to additional reserves;
• EUR 2,754,000.00, representing the remaining profit, shall be used for the increase of the Company’s share capital.
As a result of this resolution, the share capital of Tchaikapharma High Quality Medicines AD will increase by EUR 2,754,000, and following the registration of the capital increase, the Company’s registered share capital will amount to EUR 51,663,000.
By adopting this resolution, the Company continues its consistent policy of capitalizing its generated profits, thereby strengthening its equity, creating favourable conditions for future growth, and securing internal resources to finance its investment and operating activities.